FPV-brachyury-TRICOM vaccine
Term · Oncology and biomedicine · MLC-T-ONC-013774
A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.
| Identifier | MLC-T-ONC-013774 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | FPV-brachyury; FPV-brachyury boost vaccine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013774",
"term": "FPV-brachyury-TRICOM vaccine",
"field": "Oncology and biomedicine",
"definition": "A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.",
"synonyms": [
"FPV-brachyury",
"FPV-brachyury boost vaccine"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/fpv-brachyury-tricom-vaccine/"
}
Record 7,600 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.